Brick Cap

Metadata

Regulatory Status

Japan

• Commercially cultivated under the name “kuritake” and sold as a seasonal edible mushroom. Long culinary history as a traditional autumn delicacy.
• Not listed as a formal medicinal mushroom in the Japanese Pharmacopoeia. Valued primarily as a culinary species rather than a therapeutic agent.

Europe

• Mixed perception: Considered inedible or even mildly toxic in parts of Europe (particularly northern and central Europe), largely due to its bitter taste and risk of confusion with the poisonous Hypholoma fasciculare (sulphur tuft).
• No HMPC, ESCOP, or Commission E monograph exists.
• EU Novel Food status: Not specifically assessed. No history of significant food use in Europe, limiting novel food authorization prospects.

United States

• Edible status recognized by North American mycological authorities. Eaten by foragers, particularly in the northeastern United States.
• Not marketed as a dietary supplement. No GRAS determination.
• FDA: Not evaluated for any medicinal claims.

China / Korea

• Not listed in the Chinese Pharmacopoeia or Korean Pharmacopoeia. No significant traditional medicinal use documented in East Asian herbal medicine systems.

Conditions & Indications

Primary: Anti-Inflammatory Activity (Preclinical Evidence)

• COX-2 inhibition: Organic extracts (hexane, chloroform, 50% methanol) and isolated steroids from H. lateritium demonstrated significant inhibition of cyclooxygenase-2 (COX-2) protein expression in vitro. Fasciculol E, fasciculic acid B, and cerevisterol all contributed to this activity.
• Nrf2 activation: The same extracts and compounds activated the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, a master regulator of antioxidant and cytoprotective gene expression. This dual COX-2 inhibition / Nrf2 activation profile suggests anti-inflammatory potential with concurrent antioxidant defense enhancement.
• cPGES modulation: Extracts also affected cytosolic prostaglandin E2 synthase (cPGES) levels, further supporting anti-inflammatory mechanisms downstream of COX-2.

Secondary: Antioxidant Activity (Preclinical Evidence)

• Free radical scavenging: Phenolic compounds and ergosterol derivatives contribute to antioxidant capacity. Nrf2 pathway activation by cerevisterol and related steroids upregulates endogenous antioxidant enzymes (HO-1, NQO1).
• Cerevisterol activity: This fungal steroid, isolated from H. lateritium, has been independently confirmed to alleviate inflammation via suppression of MAPK/NF-kB/AP-1 and activation of the Nrf2/HO-1 signaling cascade.

Emerging/Preclinical

• Triterpene pharmacology: Twelve compounds were isolated from the methanol extract of H. lateritium, including lanosta-7,9(11)-diene-12beta,21alpha-epoxy-2alpha,3beta,24beta,25-tetraol (a novel natural product) and sublateriols A—C. Toxicity testing using bdelloid rotifer assays showed varying profiles, with cerevisterol being the most toxic and the novel lanostane compound showing no harmful effect.
• Naematolin cytotoxicity: Naematolin, a caryophyllane-type sesquiterpene originally isolated from Hypholoma species, has demonstrated cytotoxic activity in cell culture. However, its concentration in H. lateritium fruiting bodies and its relevance to oral consumption have not been systematically evaluated. [NEEDS-RESEARCH]
• Nutritional profile: As a cultivated edible in Japan, H. lateritium contributes dietary fiber (including beta-glucans), B vitamins, minerals (potassium, selenium), and ergosterol (provitamin D2), though detailed nutritional analysis specific to this species is limited.

Mechanism of Action

Primary Mechanisms

1. COX-2 / Nrf2 dual modulation: The primary pharmacological mechanism identified for H. lateritium is the simultaneous inhibition of COX-2 (reducing prostaglandin-mediated inflammation) and activation of Nrf2 (upregulating phase II antioxidant enzymes). This dual activity was demonstrated for both crude extracts and isolated compounds (fasciculols, fasciculic acid B, cerevisterol), suggesting that multiple structurally related triterpenoids and steroids contribute to the overall anti-inflammatory profile.

2. Cerevisterol-mediated anti-inflammatory signaling: Cerevisterol suppresses the MAPK/NF-kB/AP-1 signaling axis and activates the Nrf2/HO-1 cascade. This reduces pro-inflammatory mediator production (iNOS, COX-2, TNF-alpha, IL-6) while simultaneously enhancing cellular antioxidant defenses. Cerevisterol is not unique to H. lateritium but is found at appreciable levels in this species.

3. Lanostane triterpenoid activity: The fasciculol family of lanostane triterpenoids (fasciculols B through F) and their depsipeptide derivatives represent a chemically diverse group of bioactives. Fasciculic acid B contributes to COX-2 inhibition, while the broader triterpenoid profile may contribute to additional pharmacological effects that have not yet been fully characterized.

Secondary Mechanisms

• Phenolic antioxidant activity: Phenolic acids in the fruiting body contribute direct free radical scavenging capacity, complementing the enzyme-induction pathway of Nrf2 activation.
• Ergosterol provitamin D2 contribution: Ergosterol content provides potential for vitamin D2 biosynthesis upon UV exposure, contributing to the general nutritional and health-promoting profile of the species.

Clinical Evidence Summary

No human clinical trials (RCTs, open-label studies, or case series) have been published for Hypholoma lateritium. All pharmacological evidence derives from in vitro cell culture and chemical isolation studies.

Key Preclinical Studies

Evidence Limitations

• No human clinical trials exist. The entire evidence base is preclinical.
• Studies used specific solvent fractions (hexane, chloroform, 50% methanol) rather than traditional culinary preparations, limiting direct applicability to dietary consumption.
• Bioavailability of fasciculols and cerevisterol from oral consumption of cooked mushrooms has not been assessed.
• The relationship between culinary consumption quantities and pharmacologically active doses is unknown.
• The species was historically confused with Hypholoma sublateritium, and older literature may use either name. Some pharmacological data attributed to H. sublateritium applies to the same species.
• Naematolin has been studied primarily in related Hypholoma/Naematoloma species, and its specific concentration in H. lateritium fruiting bodies requires further characterization. [NEEDS-RESEARCH]

Safety Profile

General Assessment

Hypholoma lateritium has a well-established safety record as a culinary mushroom in Japan, where it has been commercially cultivated and consumed as “kuritake” for generations. Young specimens are preferred; older specimens develop bitterness. The species is generally considered safe when properly identified and prepared (cooked). Raw consumption is not recommended, consistent with general mushroom safety guidance.

Contraindications

• Pregnancy and lactation: Insufficient safety data for medicinal-dose use.
• Misidentification risk: The most significant safety concern is confusion with Hypholoma fasciculare (sulphur tuft), which contains toxic fasciculol compounds at higher concentrations and can cause severe gastrointestinal distress. Galerina marginata, which may co-occur in the same habitats, contains deadly amatoxins. Proper identification by an experienced mycologist is essential.

Drug Interactions

• No clinically documented drug interactions. Given the preclinical evidence for COX-2 inhibition, theoretical interactions with NSAIDs and anticoagulants cannot be excluded at concentrated supplemental doses, but no clinical data exists to assess significance.

Side Effects

• Bitterness in older specimens: The primary culinary complaint is that mature fruiting bodies develop a bitter taste, which is unpleasant but not toxic.
• Gastrointestinal effects: As with most wild mushrooms, improper preparation (insufficient cooking) may cause mild gastrointestinal upset in sensitive individuals.

Toxicology

• Fasciculol content: H. lateritium contains fasciculols (B, C, D, E, F), which are structurally related to the toxic fasciculols of H. fasciculare. However, the concentrations in H. lateritium are substantially lower, and the species is not considered toxic at typical culinary consumption levels. The bitter taste in older specimens may partly reflect higher fasciculol concentrations.
• No formal LD50 or subchronic toxicity studies have been published for H. lateritium extracts.

Clinical Dosage

Culinary Consumption (Japan)

• Traditional use: Consumed as a seasonal food mushroom, typically 50—150 g fresh weight per serving, sauteed, in soups, or simmered in traditional preparations.
• Frequency: Seasonal availability (autumn); consumed as part of a varied diet rather than as a daily therapeutic agent.

Extract (Research Context Only)

• No standardized medicinal extract exists. Research has used hexane, chloroform, and 50% methanol extracts for in vitro studies. These are not available as consumer products.
• No established therapeutic dose for any indication.

Dried Powder

• Not commercially available as a supplement. If dried for culinary use, general mushroom drying conventions apply.

Form Selection Guidance

Given the absence of clinical evidence for any therapeutic application, H. lateritium is best regarded as a nutritious edible mushroom with promising preclinical anti-inflammatory properties rather than a medicinal agent. Culinary consumption of properly identified, young, well-cooked specimens remains the most practical form of use.

Sources

• Vanyolos A, Dekany M, Kovacs B, et al. Extracts and steroids from the edible mushroom Hypholoma lateritium exhibit anti-inflammatory properties by inhibition of COX-2 and activation of Nrf2. Chem Biodivers. 2020;17(8):e202000391
• Baranyai B, Dekany M, Ostorharics-Horvath E, et al. Triterpenes from the mushroom Hypholoma lateritium: isolation, structure determination and investigation in bdelloid rotifer assays. Molecules. 2019;24(2):301
• Kim KH, Moon E, Choi SU, et al. Cerevisterol alleviates inflammation via suppression of MAPK/NF-kB/AP-1 and activation of the Nrf2/HO-1 signaling cascade. Biomolecules. 2020;10(2):199
• Halama M, Plich J, Jasicka-Misiak I, et al. Further biochemical profiling of Hypholoma fasciculare metabolome reveals its chemogenetic diversity. Molecules. 2021;26(11):3139
• Cornell Mushroom Blog. Hypholoma sublateritium — edible? 2006. Available at: blog.mycology.cornell.edu
• Zombiemyco. Brick Cap (Hypholoma lateritium). Available at: zombiemyco.com

Connections

• Strophariaceae edible relatives: H. lateritium belongs to the same family as Pholiota nameko (nameko) and shares ecological niches with Cyclocybe aegerita (pioppino). All three are wood-decomposing agaric mushrooms cultivated in Japan and valued for culinary use, though their pharmacological profiles differ.
• Anti-inflammatory polypore parallels: The COX-2 inhibition and Nrf2 activation demonstrated by H. lateritium triterpenoids parallels the lanostane triterpenoid pharmacology of Fomitopsis pinicola (red-belted conk) and Reishi (Ganoderma lucidum). The cerevisterol found in H. lateritium has also been isolated from Fomitopsis pinicola, suggesting shared anti-inflammatory mechanisms across wood-decomposing fungi.
• Chaga triterpenoid synergy: The antioxidant triterpenoid profile of H. lateritium suggests potential complementarity with Chaga (Inonotus obliquus), which contains structurally related lanostane triterpenoids but with a much stronger clinical evidence base.
• Toxic look-alike warning: H. lateritium must be carefully distinguished from Hypholoma fasciculare (sulphur tuft), which produces the same fasciculol triterpenoids at higher, potentially toxic concentrations. This distinction is critical for foragers and underscores the importance of accurate identification.